Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovine-derived heparin
- Development stage
- Preclinical
- Lead developer
- Changshan Kaijiejian Biopharma
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Ovine-derived heparin refers to a suite of anticoagulant products, including heparin sodium and enoxaparin sodium, derived from sheep intestinal mucosa. Developed by Changshan Kaijiejian Biopharma, these products serve as Halal and Kosher-compliant alternatives to traditional porcine-derived heparin. The mechanism of action involves binding to antithrombin III, which significantly accelerates the inactivation of clotting factors such as Factor Xa and thrombin (Factor IIa), thereby inhibiting the coagulation cascade. These sheep-derived variants are intended for use in general anticoagulation and are currently in the pharmaceutical research stage.
- Other names
- 羊源肝素Ovine-derived heparin sodiumOvine-derived enoxaparin sodium
02
Targets
F2 (Thrombin)F10 (Factor Xa)ATIII (Antithrombin III)
Beyond the preview
Go deeper on ovine-derived heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovine-derived heparin.